Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

By G. Sakoulas, P. Moise-Broder, J. Schentag, Alan Forrest, R. Moellering, G. Eliopoulos. Journal of Clinical Microbiology, 2004

887 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/0c6bd6766dd2492ca6697ddc3194a16ef1b7db92

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

1. D. Levine
2. Robert S. Daum
3. S. Cosgrove
4. J. Dalovisio
5. W. Craig
6. M. Rybak
7. J. Rotschafer
8. M. Billeter

In Infectious Diseases

1. D. Levine
2. Robert S. Daum
3. S. Cosgrove
4. J. Dalovisio
5. Henry F. Chambers
6. W. Craig
7. M. Rybak
8. J. Rotschafer

Citations in the corpus

• Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications (2010, background): “This has been driven partly by studies demonstrating poorer outcomes for vancomycin treatment of MRSA infections with higher vancomycin MICs, even when these MICs are within the susceptible range (112, 184, 298, 332).”
• Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin (2008, background): “We examined all patients treated with vancomycin for MRSA bloodstream infections at our institution, while Sakoulas and colleagues examined MRSA bacteremic patients from vancomycin refractory compassionate use studies (19).”
• Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. (2011, background): “In recent years, several centers have observed an ‘‘MIC creep’’ among MRSA isolates characterized as susceptible by CLSI criteria [331, 332], with the principle concern being the gradual loss of vancomycin activity, because clinical failures appear to be more common among those with MIC values of 2 ”
• Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America (2009, background): “Vancomycin is recommended for empirical therapy in heath care settings with an elevated prevalence of methicillin-resistant Staphylococcus aureus (MRSA); for institutions in which the preponderance of MRSA isolates have vancomycin minimum inhibitory concentration (MIC) values 12 mg/mL, alternative a”
• Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. (2019, background): “Sakoulas et al.(52) reported a significant correlation between vancomycin susceptibilities and patient outcome.”